Overview

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
0
Participant gender:
All
Summary
This study aimed to investigate the efficacy and safety of Pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as a salvage therapy for refractory Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Beijing Friendship Hospital
Treatments:
Asparaginase
Doxorubicin
Etoposide
Etoposide phosphate
Liposomal doxorubicin
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Pegaspargase
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Criteria
Inclusion Criteria:

1. Patients were older than 14 years of age

2. Diagnosed as EBV-Hemophagocytic Lymphohistiocytosis (HLH)

3. Patients did not achieve at lease partial response after initial treatment including
HLH-94 or DEP no less than 2 weeks

4. Informed consent

Exclusion Criteria:

1. Heart function above grade II (NYHA)

2. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2

3. Pregnancy or lactating Women

4. Allergic to Pegaspargase, doxorubicin or etoposide

5. Active bleeding of the internal organs

6. uncontrollable infection

7. history of acute and chronic pancreatitis

8. Participate in other clinical research at the same time